Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review

Read the full story on bayer.com (opens in a new tab)

With this approval, asundexian will become the first Factor XIa inhibitor (FXIa) available in China, to reduce the risk of stroke in adults after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack / Regulatory approval follows the China’s Center of Drug Evaluation’s Priority Review designation and is based on positive...